Reviewed,
UniProtKB/Swiss-Prot P02768 (ALBU_HUMAN)
Last modified
June 10, 2008.
Version 133.
History...
Clusters with 100%,
90%,
50% identity |
Documents (8) |
Third-party data |
Customize display | text xml rdf/xml gff fasta |
Names and origin
| Protein names | Serum albumin [Precursor] | ||||
| Gene names |
| ||||
| Organism | Homo sapiens (Human) | ||||
| Taxonomic identifier | 9606 [NCBI] | ||||
| Taxonomic lineage | Eukaryota › Metazoa › Chordata › Craniata › Vertebrata › Euteleostomi › Mammalia › Eutheria › Euarchontoglires › Primates › Haplorrhini › Catarrhini › Hominidae › Homo | ||||
| Protein existence | Evidence at protein level. |
General annotation (Comments)
| Function | Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood. |
| Subcellular location | Secreted. |
| Tissue specificity | Plasma. |
| Post-translational modification | Kenitra variant is partially O-glycosylated at Thr-620. It has two new disulfide bonds Cys-600 to Cys-602 and Cys-601 to Cys-606. Glycated in diabetic patients. |
| Polymorphism | The sequence shown is that of variant albumin A. |
| Involvement in disease | Defects in ALB are a cause of familial dysalbuminemic hyperthyroxinemia (FDH) [MIM:103600]. FDH is a form of euthyroid hyperthyroxinemia that is due to increased affinity of ALB for T(4). It is the most common cause of inherited euthyroid hyperthyroxinemia in Caucasian population. A variant structure of albumin could lead to increased binding of zinc resulting in an asymptomatic augmentation of zinc concentration in the blood [MIM:194470]. |
| Miscellaneous | Acetylated on Lys-223 by acetylsalicylic acid. |
| Sequence similarities | Belongs to the ALB/AFP/VDB family. Contains 3 albumin domains. |
| Caution | A peptide arising from positions 166 to 174 was originally (Ref.23 and Ref.24) termed neurotensin-related peptide (NRP) or kinetensin and was thought to regulates fat digestion, lipid absorption, and blood flow. |
Ontologies
Alternative products
| This entry describes 2 isoforms produced by alternative splicing. [Align] [Select] Isoform 1 (identifier: P02768-1) Isoform 2 (identifier: P02768-2) |
Sequence annotation (Features)
| Feature key | Position(s) | Length | Description | Graphical view | ||||||
Molecule processing | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Signal peptide | 1 – 18 | 18 | ||||||||
| Propeptide | 19 – 24 | 6 | ||||||||
| Chain | 25 – 609 | 585 | Serum albumin | |||||||
Regions | ||||||||||
| Domain | 25 – 205 | 181 | Albumin 1 | |||||||
| Domain | 212 – 397 | 186 | Albumin 2 | |||||||
| Domain | 404 – 595 | 192 | Albumin 3 | |||||||
Sites | ||||||||||
| Metal binding | 27 | 1 | Copper By similarity | |||||||
| Binding site | 264 | 1 | Bilirubin Potential | |||||||
| Site | 28 | 1 | Not glycated | |||||||
| Site | 44 | 1 | Not glycated | |||||||
| Site | 65 | 1 | Not glycated | |||||||
| Site | 88 | 1 | Not glycated | |||||||
| Site | 97 | 1 | Not glycated | |||||||
| Site | 117 | 1 | Not glycated | |||||||
| Site | 130 | 1 | Not glycated | |||||||
| Site | 160 | 1 | Not glycated | |||||||
| Site | 183 | 1 | Not glycated | |||||||
| Site | 198 | 1 | Not glycated | |||||||
| Site | 205 | 1 | Not glycated | |||||||
| Site | 214 | 1 | Not glycated | |||||||
| Site | 219 | 1 | Not glycated | |||||||
| Site | 223 | 1 | Aspirin-acetylated lysine | |||||||
| Site | 229 | 1 | Not glycated | |||||||
| Site | 236 | 1 | Not glycated | |||||||
| Site | 264 | 1 | Not glycated | |||||||
| Site | 286 | 1 | Not glycated | |||||||
| Site | 298 | 1 | Not glycated | |||||||
| Site | 310 | 1 | Not glycated | |||||||
| Site | 383 | 1 | Not glycated | |||||||
| Site | 396 | 1 | Not glycated | |||||||
| Site | 413 | 1 | Not glycated | |||||||
| Site | 426 | 1 | Not glycated | |||||||
| Site | 438 | 1 | Not glycated | |||||||
| Site | 456 | 1 | Not glycated | |||||||
| Site | 460 | 1 | Not glycated | |||||||
| Site | 490 | 1 | Not glycated | |||||||
| Site | 499 | 1 | Not glycated | |||||||
| Site | 524 | 1 | Not glycated | |||||||
| Site | 543 | 1 | Not glycated | |||||||
| Site | 548 | 1 | Not glycated | |||||||
| Site | 562 | 1 | Not glycated | |||||||
| Site | 565 | 1 | Not glycated | |||||||
| Site | 581 | 1 | Not glycated | |||||||
| Site | 584 | 1 | Not glycated | |||||||
| Site | 588 | 1 | Not glycated | |||||||
| Site | 598 | 1 | Not glycated | |||||||
Amino acid modifications | ||||||||||
| Glycosylation | 36 | 1 | N-linked (Glc) (glycation) Probable | |||||||
| Glycosylation | 75 | 1 | N-linked (Glc) (glycation); in vitro | |||||||
| Glycosylation | 161 | 1 | N-linked (Glc) (glycation); in vitro | |||||||
| Glycosylation | 186 | 1 | N-linked (Glc) (glycation); in vitro | |||||||
| Glycosylation | 223 | 1 | N-linked (Glc) (glycation); in vitro | |||||||
| Glycosylation | 249 | 1 | N-linked (Glc) (glycation); in vitro | |||||||
| Glycosylation | 257 | 1 | N-linked (Glc) (glycation) Probable | |||||||
| Glycosylation | 300 | 1 | N-linked (Glc) (glycation); in vitro | |||||||
| Glycosylation | 305 | 1 | N-linked (Glc) (glycation) | |||||||
| Glycosylation | 337 | 1 | N-linked (Glc) (glycation); in vitro | |||||||
| Glycosylation | 341 | 1 | N-linked (Glc) (glycation) Probable | |||||||
| Glycosylation | 342 | 1 | N-linked (GlcNAc...); in variant Redhill | |||||||
| Glycosylation | 347 | 1 | N-linked (Glc) (glycation); in vitro | |||||||
| Glycosylation | 375 | 1 | N-linked (Glc) (glycation) Probable | |||||||
| Glycosylation | 402 | 1 | N-linked (Glc) (glycation); in vitro | |||||||
| Glycosylation | 437 | 1 | N-linked (Glc) (glycation); in vitro | |||||||
| Glycosylation | 463 | 1 | N-linked (Glc) (glycation) | |||||||
| Glycosylation | 468 | 1 | N-linked (Glc) (glycation); in vitro | |||||||
| Glycosylation | 518 | 1 | N-linked (GlcNAc...); in variant Casebrook | |||||||
| Glycosylation | 549 | 1 | N-linked (Glc) (glycation) | |||||||
| Glycosylation | 558 | 1 | N-linked (Glc) (glycation) Probable | |||||||
| Glycosylation | 560 | 1 | N-linked (Glc) (glycation); in vitro | |||||||
| Glycosylation | 569 | 1 | N-linked (Glc) (glycation); in vitro | |||||||
| Glycosylation | 597 | 1 | N-linked (Glc) (glycation); in vitro | |||||||
| Disulfide bond | 77 ↔ 86 | |||||||||
| Disulfide bond | 99 ↔ 115 | |||||||||
| Disulfide bond | 114 ↔ 125 | |||||||||
| Disulfide bond | 148 ↔ 193 | |||||||||
| Disulfide bond | 192 ↔ 201 | |||||||||
| Disulfide bond | 224 ↔ 270 | |||||||||
| Disulfide bond | 269 ↔ 277 | |||||||||
| Disulfide bond | 289 ↔ 303 | |||||||||
| Disulfide bond | 302 ↔ 313 | |||||||||
| Disulfide bond | 340 ↔ 385 | |||||||||
| Disulfide bond | 384 ↔ 393 | |||||||||
| Disulfide bond | 416 ↔ 462 | |||||||||
| Disulfide bond | 461 ↔ 472 | |||||||||
| Disulfide bond | 485 ↔ 501 | |||||||||
| Disulfide bond | 500 ↔ 511 | |||||||||
| Disulfide bond | 538 ↔ 583 | |||||||||
| Disulfide bond | 582 ↔ 591 | |||||||||
Natural variations | ||||||||||
| Alternative sequence | 43 – 234 | 192 | Missing in isoform 2. | |||||||
| Natural variant | 23 | 1 | R → C in Redhill/Malmo-I/Tradate; associated with T-344 in Redhill. | |||||||
| Natural variant | 23 | 1 | R → H in Fukuoka-2/Lille/Taipei/Varese/Komagome-3. | |||||||
| Natural variant | 24 | 1 | R → L in Jaffna. | |||||||
| Natural variant | 24 | 1 | R → P in Takefu/Honolulu-1. | |||||||
| Natural variant | 24 | 1 | R → Q in Christchurch/Honolulu-2. | |||||||
| Natural variant | 25 | 1 | D → V in Bleinheim/Iowa city-2. | |||||||
| Natural variant | 27 | 1 | H → Q in Nagasaki-3. | |||||||
| Natural variant | 27 | 1 | H → Y in Larino. | |||||||
| Natural variant | 73 | 1 | F → Y | |||||||
| Natural variant | 84 | 1 | E → K in Torino. | |||||||
| Natural variant | 87 | 1 | D → N in Malmo-95/Dalakarlia. | |||||||
| Natural variant | 90 | 1 | L → P in FDH. | |||||||
| Natural variant | 106 | 1 | E → K in Vibo Valentia. | |||||||
| Natural variant | 121 | 1 | E → G | |||||||
| Natural variant | 138 | 1 | R → G in Yanomama-2. | |||||||
| Natural variant | 143 | 1 | E → K in Nagoya. | |||||||
| Natural variant< | ||||||||||

Clusters with